Cargando…

A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro

Dovitinib (TKI258) is a small molecule multi-kinase inhibitor currently in clinical phase I/II/III development for the treatment of various types of cancers. This drug has a safe and effective pharmacokinetic/pharmacodynamic profile. Although dovitinib can bind several kinases at nanomolar concentra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yura, Bae, Kyoung Jun, Chon, Hae Jung, Kim, Seong Hwan, Kim, Soon Ae, Kim, Jiyeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Molecular and Cellular Biology 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870186/ https://www.ncbi.nlm.nih.gov/pubmed/27025387 http://dx.doi.org/10.14348/molcells.2016.2300

Ejemplares similares

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
por: Yadav, Shalini S., et al.
Publicado: (2017)

Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells
por: Lee, Yura, et al.
Publicado: (2017)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
por: Weiss, Johanna, et al.
Publicado: (2014)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells
por: Hänze, Jörg, et al.
Publicado: (2013)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma
por: AlRabiah, Haitham, et al.
Publicado: (2020)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Pilot study of dovitinib in patients with von Hippel-Lindau disease
por: Pilié, Patrick, et al.
Publicado: (2018)

Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion
por: Qiu, Xu-Hua, et al.
Publicado: (2017)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Dovitinib induces mitotic defects and activates the G(2) DNA damage checkpoint
por: Man, Wing Yu, et al.
Publicado: (2014)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

AB011. Thymoma in patient receiving tyrosine kinase inhibitor (TKI) treatment: morphological aspects and surgical approach
por: Cattaneo, Margherita, et al.
Publicado: (2022)

Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
por: Shivapurkar, Narayan, et al.
Publicado: (2017)

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies
por: Taylor, Matthew H., et al.
Publicado: (2020)

Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity
por: Paschke, L., et al.
Publicado: (2019)

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
por: Fontes-Sousa, Mário, et al.
Publicado: (2022)

Health Tract, No. 258: Courting
Publicado: (1866)

Acceleration of osteoblast differentiation by a novel osteogenic compound, DMP-PYT, through activation of both the BMP and Wnt pathways
por: Bae, Su Jung, et al.
Publicado: (2017)

Gingival fibroblasts prevent BMP‐mediated osteoblastic differentiation
por: Ghuman, Mandeep S., et al.
Publicado: (2018)

Poly(Alkyl‐Terphenyl Piperidinium) Ionomers and Membranes with an Outstanding Alkaline‐Membrane Fuel‐Cell Performance of 2.58 W cm(−2)
por: Chen, Nanjun, et al.
Publicado: (2021)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Insights into the osteoblast precursor differentiation towards mature osteoblasts induced by continuous BMP-2 signaling
por: Zouani, Omar F., et al.
Publicado: (2013)

Memorandum: LEAR polarization M258
por: Önel, Y M, et al.
Publicado: (1986)

Hea Lthtract, No. 258: Physiology of Repentance
Publicado: (1866)

BRITER: A BMP Responsive Osteoblast Reporter Cell Line
por: Yadav, Prem Swaroop, et al.
Publicado: (2012)

TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation
por: Chen, Guiqian, et al.
Publicado: (2012)

Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer
por: Wei, Zhangjing, et al.
Publicado: (2017)

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)
por: Luo, Jingtao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7tbkd4as9es8djue4jaetmtii